Form 4: Oncology Institute Director Converts Preferred Stock to Over 779,000 Common Shares

Richard A. Barasch, a Director and 10% Owner of The Oncology Institute, Inc., converted a significant portion of his Class A Common Equivalent Preferred Stock into common shares across two transactions in mid-June 2025.

Summary

• Richard A. Barasch, a Director and 10% Owner of The Oncology Institute, Inc. (TOI), reported changes in his beneficial ownership.
• On June 17, 2025, Mr. Barasch converted 1,595 shares of Class A Common Equivalent Preferred Stock into 159,500 shares of Common Stock.
• This conversion resulted in a direct beneficial ownership of 1,935,141 shares of Common Stock.
• On June 18, 2025, an additional 6,204 shares of Class A Common Equivalent Preferred Stock were converted into 620,400 shares of Common Stock.
• Following the second conversion, Mr. Barasch's indirect beneficial ownership, held by the Helen Barasch Family Trust #1, increased to 2,555,541 shares of Common Stock.
• Each share of Preferred Stock is convertible into 100 shares of Common Stock, and no consideration was paid for these conversions.
• The Preferred Stock is convertible at any time at the option of the reporting person and has no expiration date.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director and 10% owner is increasing their common stock holdings, which can be interpreted as a sign of confidence in the company's future. While it's a conversion and not a direct purchase, it still reflects a strategic decision to hold more common equity.

Positives

• A Director and 10% Owner, Richard A. Barasch, has increased his common stock holdings in The Oncology Institute, Inc. through conversion, which can signal confidence in the company's future prospects.
• The conversion of preferred stock into common stock simplifies the capital structure by reducing the number of preferred shares outstanding.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a standard insider transaction report and does not provide information relevant to broader industry trends or competitive analysis within the healthcare or oncology sector.

Related Party Transactions

• The indirect beneficial ownership of 2,555,541 shares of Common Stock is held by the Helen Barasch Family Trust #1, which is an affiliate of the reporting person, Richard A. Barasch. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders may view the increased common stock holdings by a director and 10% owner as a positive signal of management's alignment with shareholder interests and confidence in the company's long-term value.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Beneficial Ownership, Stock Conversion, Preferred Stock, Common Stock, The Oncology Institute Inc., TOI, Director, 10% Owner